Allmed Solutions Ltd. (ALMD)
TASE TASE Primary Summary
Allmed Solutions Ltd. (ALMD) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Allmed Solutions Ltd. ever had a stock split?
Allmed Solutions Ltd. Profile
| Health Care Technology Industry | Healthcare Sector | Benjamin Spenser CEO | TASE Exchange | IL0011014508 ISIN |
| Israel Country | 19 Employees | - Last Dividend | 8 Apr 2015 Last Split | - IPO Date |
Overview
Allmed Solutions Ltd, formerly known as Allium Medical Solutions Ltd, stands as a pioneer in the medical industry by focusing on the development, manufacture, and international marketing of minimally invasive medical products. Founded in 2004 and headquartered in Caesarea, Israel, the company has cemented its presence not just domestically but also on the global stage. Allmed Solutions dedicates its resources to addressing critical health issues, with a particular emphasis on innovative solutions for type 2 diabetes in obese and overweight patients, among other medical conditions. Through its commitment to excellence and innovation, Allmed Solutions continues to make significant advancements in medical technology, contributing to the improvement of patient outcomes worldwide.
Products and Services
- Medical Devices for Type 2 Diabetes
- ProCatid System
- Mitral Valve Regurgitation Solution
At the forefront of Allmed Solutions' product lineup are its medical devices designed specifically for the treatment of type 2 diabetes in obese and overweight patients. These devices aim to provide minimally invasive options to manage and potentially improve the condition of those struggling with this common yet challenging health issue, emphasizing the company's commitment to tackling diabetes through innovative medical solutions.
The ProCatid system represents another significant achievement in Allmed Solutions' portfolio. This distal embolic protection system comprises an independent filter unit that boasts the ability to be delivered, locked, and deployed on any commercially marketed guide wires. The design and functionality of the ProCatid system highlight Allmed Solutions' dedication to advancing minimally invasive technologies, contributing to safer and more effective treatments for patients undergoing procedures that risk embolic events.
Expanding its array of medical innovations, Allmed Solutions is also involved in the development of a solution for mitral valve regurgitation, a condition characterized by the backflow of blood due to the improper closure of the mitral valve. This endeavor into cardiac health further exemplifies Allmed Solutions' versatile approach to addressing a wide range of medical challenges through the deployment of cutting-edge technology and research.
